Best Practices In Small Molecule Out-Licensing
The client wanted to understand the best practices followed by pharmaceutical companies in the USA and Europe for out-licensing of small molecules (pharmaceutical drugs) and implement them into their own internal processes before looking out for out-licensing partners. The client was interested in gathering the following information: Successful procedures of out-licensing of discovery or pre-clinical stage small molecules Process of finding suitable partners for out-licensing
Research findings were delivered to the client as a custom report covering: Profiles of the targeted companies with respect to their practices followed for selection of out-licensing partner, number of partners they collaborate for a product, payment terms, and licensing fee. Analysis of out-licensing process across the target regions Information on out-licensing partner search Conclusions and recommendations
We conducted research through: Primary research: 10-15 interviews with senior executives from out-licensing companies such as 4SC, Array Biopharma, Bicycle Therapeutics, Saniona, Vernalis and others Secondary research: We referred to resources such as industry associations, news sources and blogs, company filings, annual reports, and other publicly available information
The client was very satisfied with the findings of our study. The report helped them to successfully identify suitable out-licensing partners in the USA and Europe.